Talus Bio is a drug discovery biotech company that develops drugs targeting undruggable transcription factors using AI.
Talus Bio has raised $11.2M in total funding. The most recent round was Seed. The last funding was announced in August 2024.
Talus Bio's investors include National Science Foundation, Y Combinator, Pioneer Fund, Fifty Years, NFX.
Talus Bio is headquartered in Seattle, United States.
Talus Bio is a drug discovery biotech company that develops drugs targeting undruggable transcription factors using AI.
Talus Bio is at the Seed stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Talus Bio — Funding & Investors." VCBacked, August 20, 2024, https://www.vcbacked.co/company/talus-bio. Accessed July 20, 2026.
VCBacked. (2024). Talus Bio — Funding & Investors. Retrieved July 20, 2026, from https://www.vcbacked.co/company/talus-bio
{{cite web |title=Talus Bio — Funding & Investors |url=https://www.vcbacked.co/company/talus-bio |website=VCBacked |access-date=July 20, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated